A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin - Wei, L; Zhang, M; Xu, M (J Gastroenterol Hepatol, 2016)
, et al.